ライフサイエンスコーパス: atherogenic

1 However, T(reg) cells can become pro-atherogenic.

2 oth APOC3 and APOE content, are particularly atherogenic.

3 nhibit insulin-induced p-Tyr911 and its anti-atherogenic actions (p-Akt/eNOS) in endothelial cells.

4 , synthetic LXR agonists still elicited anti-atherogenic activity in the absence of hepatic LXRalpha,

5 Moreover, some T cells seem to have both pro-atherogenic and anti-atherogenic functions.

6 en changes in CaI and on-treatment levels of atherogenic and antiatherogenic lipoproteins, and C-reac

7 es (cART) are clearly beneficial, but can be atherogenic and could increase stroke risk.

8 eflects the significant lifestyle effects on atherogenic and diabetogenic fat depots.

9 poproteins, epsilon4 allele had consistently atherogenic and epsilon2 protective effect on particle c

10 ue neutrophil extracellular traps, which are atherogenic and increased by diabetes mellitus.

11 ve pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines.

12 ng the mechanisms whereby statins reduce the atherogenic and inflammatory phenotype resulting from a

13 ream products, and related genes involved in atherogenic and inflammatory processes in vivo in humans

14 use some experimental studies have suggested atherogenic and lipotoxicity effects of long-chain and v

15 In vivo validation of these pro-atherogenic and osteogenic genes also demonstrates a bro

16 his leads to an up-regulation of several pro-atherogenic and pro-fibrotic targets including ICAM-1 an

17 gh plasmatic levels of pro-inflammatory, pro-atherogenic and pro-thrombotic adipokines.

18 The atherogenic and thrombogenic indexes (AI and TI, respect

19 with 10.0 g TRP supplementation reduced the atherogenic and thrombogenic indices of broiler chicken

20 The lipid indices (PUFA/SFA ratio, atherogenic and thrombogenic indices) for both UAE-E:W e

21 licit a pro-inflammatory cascade known to be atherogenic and to precipitate acute ischemic events.

22 .36+/-6.76%) which led to low omega6/omega3, atherogenic, and thrombogenic index.

23 existence, origin, and function of putative atherogenic antibodies are controversial.

24 apies aiming to reduce circulating levels of atherogenic apoB lipoproteins.

25 n of VLDL secretion reduces plasma levels of atherogenic apolipoprotein B (apoB) lipoproteins but can

26 lbumin excretion relates to higher levels of atherogenic apolipoprotein B fractions in the nondiabeti

27 CHD risk by lowering concentrations of other atherogenic, apolipoprotein B-containing lipoproteins (s

28 s mice were also backcrossed onto an Apoe KO atherogenic background and fed a western-type diet (WTD)

29 Additionally, in a pro-atherogenic background, liver-specific deletion of LXRal

30 venous ECs switched its phenotype toward pro-atherogenic by up-regulating the expression of inflammat

31 atients with pediatric psoriasis have a more atherogenic cardiometabolic risk profile, with evidence

32 Atherogenic characteristics of MG(min)-LDL were characte

33 lating levels of CCL11-a proinflammatory and atherogenic chemokine also known as eotaxin (P for rs600

34 In atherogenic cholesterol-treated murine aortic endothelia

35 ins a target of interest because of its anti-atherogenic, cholesterol removal, and anti-inflammatory

36 ptor (LDLR) plays a pivotal role in clearing atherogenic circulating low-density lipoprotein (LDL) ch

37 nhibitory effect on intestinal production of atherogenic CM particles.

38 = 0.019), and reduced detoxification of the atherogenic compound methylglyoxal (+54%, P = 0.008).

39 These findings suggest that atherogenic conditions critically regulate platelet CD36

40 s an important effector molecule integrating atherogenic conditions to direct inflammatory cell entry

41 oronary smooth muscle cells upon exposure to atherogenic conditions.

42 ssified into eight groups: a normal control, atherogenic control and six other experimental groups (f

43 vide key signals for mDC differentiation and atherogenic conversion.

44 contribute to T cells re-activation and pro-atherogenic cytokine production.

45 The anti-atherogenic cytokine TGF-beta inhibits macrophage foam c

46 release of interleukin-1beta and -18, potent atherogenic cytokines.

47 nthesized H2S protects vascular tissues from atherogenic damage by reducing vessel intimal proliferat

48 mice were fed with either a high-cholesterol atherogenic diet (HCD) or matching normal diet (ND), res

49 atherosclerosis was induced in 18 rabbits by atherogenic diet and double balloon endothelial denudati

50 ression of vascular damage in response to an atherogenic diet by quantifying the in vivo accumulation

51 nd tempers chronic inflammatory responses to atherogenic diet by restraining proinflammatory signalin

52 n rats as well as rabbits, fed on normal and atherogenic diet containing 10% of SL1 and SL2 (experime

53 Apo E-KO mice were fed with an atherogenic diet containing 2% (w/w) PS-DHA for 7 weeks.

54 Prolonged exposure to an atherogenic diet decreases LTL and increases LTL attriti

55 CSE-knockout mice fed with atherogenic diet developed early fatty streak lesions in

56 iac, hepatic and renal antioxidant status of atherogenic diet fed hamsters.

57 oprotein E-deficient (apoE(-/-)) mice fed an atherogenic diet for 12 weeks.

58 ide transfer protein gene, were placed on an atherogenic diet for 16 weeks, then either made diabetic

59 All mice then were fed an atherogenic diet for 16 weeks.

60 Reversa mice were fed an atherogenic diet for 16 weeks.

61 Atherogenic diet induced a significant (P<0.001) increas

62 ssess an antioxidant protective role against atherogenic diet induced oxidative stress in cardiac, he

63 Atherogenic diet influences LTL, and LTL is a potential

64 partly contribute to the inhibitory role of atherogenic diet on lung tumorigenesis.

65 ificantly inhibited the alteration effect of atherogenic diet on the lipid profile and antioxidant en

66 ant administration of allosamidin and fed an atherogenic diet showed aggravated atherosclerotic lesio

67 ntrol and six other experimental groups (fed atherogenic diet supplemented with different doses of P.

68 -/-) and APOA1 (tg/tg)/Apoe (-/-) mice to an atherogenic diet to develop advanced plaques.

69 /+) littermates, followed by feeding them an atherogenic diet to produce atherosclerosis.

70 When fed an atherogenic diet, MAKO/LDLRKO mice displayed exacerbated

71 tial and peri-adventitial microvessels after atherogenic diet, suggestive of newly formed vasa vasoru

72 streptozotocin-induced diabetes consuming an atherogenic diet, without changes in gross glomerular mo

73 Consistently, high cholesterol atherogenic diet-challenged Sort1 knock-out mice showed

74 nd fatty acid metabolism in high cholesterol atherogenic diet-fed mice.

75 -1alpha) and in vivo lipopolysaccharide- and atherogenic diet-induced NF-kappaB activation.

76 culating proatherogenic cells in mice fed an atherogenic diet.

77 tery and abdominal aorta of 7 rabbits fed an atherogenic diet.

78 tery and abdominal aorta of 7 rabbits fed an atherogenic diet.

79 ty lipoprotein receptor Ldlr(-/-) mice on an atherogenic diet.

80 wine by 6 months' feeding of a hypercaloric, atherogenic diet.

81 etes, obesity, a sedentary lifestyle, and an atherogenic diet.

82 n observed in the arteries of rabbits fed on atherogenic diets was significantly reduced when structu

83 ipids and lipid deposition in animals fed on atherogenic diets.

84 Atherogenic dyslipidemia (triglycerides >150 mg/dl [1.69

85 c target for the treatment and prevention of atherogenic dyslipidemia and NAFLD in young insulin resi

86 vo lipogenesis, promoting the development of atherogenic dyslipidemia and NAFLD.

87 nonalcoholic fatty liver disease (NAFLD) and atherogenic dyslipidemia associated with the metabolic s

88 hat targeting the central abnormality of the atherogenic dyslipidemia complex, the elevation of trigl

89 e strategy in correcting most aspects of the atherogenic dyslipidemia complex, thereby preventing CVD

90 decades have resulted in an epidemic of the "atherogenic dyslipidemia complex," the main features of

91 s that are known to modify components of the atherogenic dyslipidemia complex.

92 ing new therapeutic strategies to modify the atherogenic dyslipidemia complex.

93 lights the potential importance of targeting atherogenic dyslipidemia in diabetic patients with coron

94 VD risk, at least in part through effects on atherogenic dyslipidemia, a cluster of traits including

95 ue to be a viable treatment option for mixed atherogenic dyslipidemia, and recent reports from clinic

96 poprotein (sdLDL) particles are hallmarks of atherogenic dyslipidemia, and their cholesterol content

97 benefit from fibrate even in the absence of atherogenic dyslipidemia.

98 ated blood pressure, insulin resistance, and atherogenic dyslipidemia.

99 terogeneous and to depend on the presence of atherogenic dyslipidemia.

100 fibrate treatment, in addition to those with atherogenic dyslipidemia.

101 ified molecular explanation for fatty liver, atherogenic dyslipoproteinemia, hyperglycemia, and hence

102 tion, setting the stage for a potential anti-atherogenic effect of this mutation.

103 A number of studies support the anti-atherogenic effect of wine compounds.

104 These direct atherogenic effects are dependent on apoCIII.

105 These potentially pro-atherogenic effects are however counteracted by neutrope

106 or 2 (apoER2) results in either pro- or anti-atherogenic effects depending on the ligand.

107 sis that the vasculature is altered by known atherogenic effects of chronic HAART or the prolonged in

108 ves of this study were to determine the anti-atherogenic effects of Enano and L-Enano in LDL receptor

109 nt sterol levels and CVD, thereby suggesting atherogenic effects of plant sterols or of cholesterol u

110 he exposure of the entire vasculature to the atherogenic effects of systemic risk factors, atheroscle

111 ture model systems revealed protective, anti-atherogenic effects of the cytokine interleukin-33 (IL-3

112 Overall, the beneficial anti-atherogenic effects of weight loss can be observed even

113 e, FDR < 2.0 x 10(-16)), accompanied by anti-atherogenic effects on transcriptomic markers, decreased

114 e to its prothrombotic, proinflammatory, and atherogenic effects.

115 nique oxylipin signature that promotes a pro-atherogenic endothelial phenotype.

116 nhancer-mediated inflammatory transcription, atherogenic endothelial responses, and atherosclerosis i

117 livery of therapeutics such as siRNAs to pro-atherogenic endothelium.

118 d that shear stress conditions that modulate atherogenic events also regulate Tie1 expression.

119 ion signaling pathways that are activated by atherogenic factors are poorly defined.

120 At inflammatory sites, where atherogenic factors such as immune complexes and/or path

121 , which can be initiated by physiological or atherogenic factors, is a pivotal process in atherogenes

122 lammatory disease driven by lipids and other atherogenic factors.

123 rosine kinase Tie1 was evident at regions of atherogenic flow in mature animals.

124 oprotein (apo) A-I mediates many of the anti-atherogenic functions attributed to high density lipopro

125 In addition to these indirect atherogenic functions mediated through dyslipidemia, rec

126 ngthen the theory that apoCIII exerts strong atherogenic functions through both indirect and direct m

127 s seem to have both pro-atherogenic and anti-atherogenic functions.

128 ocked the increased lipid deposition and the atherogenic gene expression in the arterial wall and aor

129 which induces endothelial expression of pro-atherogenic genes and the subsequent endothelial dysfunc

130 ely regulated expression of IFNgamma-induced atherogenic genes in human EC and SMC by modulating STAT

131 d an increase in functionally important anti-atherogenic high-density lipoprotein -associated metabol

132 After having been fed an atherogenic high-fat (AHF) diet, massive accumulation of

133 Some mice were placed on an atherogenic high-fat diet (16% fat, 41% carbohydrate, an

134 Saturated FA, insulin signals, or an atherogenic high-fat diet can induce CREBH activation in

135 When placed on the atherogenic high-fat diet, the KO mice developed feature

136 ncover A20 as a key physiologic regulator of atherogenic IFNgamma/STAT1 signaling.

137 S100A8/A9, which are atherogenic in mice and are expressed in human atheroscl

138 xcept possibly in patients with an increased atherogenic index (triglyceride : HDL-C ratio), or have

139 rol, triglycerides, LDL-cholesterol, and the atherogenic index of plasma (AIP) suggesting its hypolip

140 imed to evaluate the association between the atherogenic index of plasma (AIP), which has been sugges

141 d total cholesterol in healthy rats, but not atherogenic index.

142 w, how endothelial activation contributes to atherogenic inflammation is not well understood.

143 responses and as a key contributor to early atherogenic inflammation.

144 timulated by TNFalpha provided a readout for atherogenic inflammation.

145 erto unknown link between Nck1 and IRAK-1 in atherogenic inflammation.

146 mellitus skews plaque macrophages toward an atherogenic inflammatory M1 phenotype instead of toward

147 romatin-dependent signal transduction in the atherogenic inflammatory response, we characterized the

148 Platelet-derived exosomes mediate platelet atherogenic interactions with endothelial cells and mono

149 mations: (a) initial rapid generation of the atherogenic intermediate gammaBB, followed by (b) transf

150 (TMAO) via a multistep pathway involving an atherogenic intermediate, gamma-butyrobetaine (gammaBB).

151 xidative stress are up-regulated by the anti-atherogenic laminar blood flow often seen in straight or

152 ntly blocked the shift in buoyancy from less atherogenic lb-LDL to highly atherogenic sd-LDL, restori

153 atherogenicity that provides a new route to atherogenic LDL and may explain the escalation of cardio

154 equently led to the attenuation of the early atherogenic lesion.

155 es NF-kappaB-dependent inflammation in early atherogenic lesions, and knocking down RIPK1 will reduce

156 ared with SFAs, with smaller improvements in atherogenic lipid concentrations in obese than in normal

157 genes scavenger receptor BI (SR-BI), an anti-atherogenic lipid exchange mediator, activated internali

158 I, -69.64% to -25.35%]; P < 0.001] and other atherogenic lipid fractions, and it reduced all-cause mo

159 Evolocumab also significantly reduced other atherogenic lipid levels, including non-high-density lip

160 pothesized that orally ingested UFP promoted atherogenic lipid metabolites in both the intestine and

161 obiota composition, accompanied by increased atherogenic lipid metabolites.

162 flammation, heightened oxidative stress, and atherogenic lipid profile that may increase women's risk

163 on-black race, metabolic risks, an increased atherogenic lipid profile, and elevated ALT overtime.

164 he allergic LDLr(-/-) group despite the more atherogenic lipid profile.

165 esterol reduction with regard to a patient's atherogenic lipid profile.

166 tration <20 ng/mL, is correlated with a more atherogenic lipid profile.

167 Pro-atherogenic lipids and atherosclerosis are greater in XX

168 We tested whether levels of atherogenic lipids and lipoproteins differed significant

169 ficacy and safety of mipomersen for reducing atherogenic lipids and lipoproteins in patients with hyp

170 At the top of the checklist for reducing atherogenic lipids and recurrent event risk postmyocardi

171 In addition to reduction in atherogenic lipids, it may also contribute to improvemen

172 hsCRP, and fibrinogen with little change in atherogenic lipids.

173 8,924) 1 to 12 months post-ACS with elevated atherogenic lipoprotein levels despite high-intensity st

174 tes most of a 24-h cycle and better captures atherogenic lipoprotein levels.

175 idual larval zebrafish and collect images of atherogenic lipoprotein localization in an intact organi

176 terolemia (FH) are characterized by elevated atherogenic lipoprotein particles, predominantly low-den

177 7-fold increase in plasma cholesterol and an atherogenic lipoprotein profile with increased levels of

178 s associated with dyslipidemia, particularly atherogenic lipoprotein subparticles, the impact of thes

179 Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein.

180 ) the association between very low levels of atherogenic lipoproteins achieved with statin therapy an

181 Levels of atherogenic lipoproteins achieved with statin therapy ar

182 enetic associations between plasma levels of atherogenic lipoproteins and 25(OH)D were examined in </

183 ervationally is simply a marker for elevated atherogenic lipoproteins and question a role for vitamin

184 Statins effectively lower atherogenic lipoproteins and result in clinically signif

185 t a sensitive and specific approach to study atherogenic lipoproteins and their genetic and small mol

186 Among patients with recent ACS and elevated atherogenic lipoproteins despite intensive statin therap

187 n ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therap

188 ts with acute coronary syndrome and elevated atherogenic lipoproteins despite optimized statin treatm

189 isation and who had raised concentrations of atherogenic lipoproteins despite use of high-intensity s

190 gy to target human ANGPTL3 reduced levels of atherogenic lipoproteins in humans.

191 ion of atherosclerosis and reduced levels of atherogenic lipoproteins in mice.

192 Evolocumab markedly reduces atherogenic lipoproteins in patients with type 2 diabete

193 locumab is an effective therapy for lowering atherogenic lipoproteins in PLHIV with high cardiovascul

194 Plasma contains atherogenic lipoproteins of hepatic origin in the fastin

195 Blacks have lower concentrations of atherogenic lipoproteins that contain apo C-III than do

196 ency of TGH in mice lowers plasma lipids and atherogenic lipoproteins without inducing hepatic steato

197 cholesterol and AF extended to several other atherogenic lipoproteins, and these associations are unl

198 )D levels are associated with high levels of atherogenic lipoproteins, but whether these 2 risk facto

199 recent acute coronary syndrome and elevated atherogenic lipoproteins, despite intensive statin thera

200 Lowering of atherogenic lipoproteins, including low-density lipoprot

201 cardiometabolic biomarkers defined by lipid, atherogenic lipoproteins, inflammation and insulin resis

202 tein-B (ApoB) is the structural component of atherogenic lipoproteins, lipid-rich particles that driv

203 s, evolocumab decreased the concentration of atherogenic lipoproteins, particularly LDL, by accelerat

204 e, along with serum cholesterol measures and atherogenic lipoproteins.

205 impart anti-inflammatory effects by reducing atherogenic lipoproteins.

206 polipoprotein B, reduces LDL cholesterol and atherogenic lipoproteins.

207 ly decreased, indicating reductions in total atherogenic lipoproteins.

208 antly increased plasma total cholesterol and atherogenic low-density lipoprotein cholesterol levels i

209 one marrow from male Flna (o/fl)/ LC mice to atherogenic low-density lipoprotein receptor-deficient (

210 Lipoprotein(a) is an atherogenic low-density lipoprotein-like particle and ci

211 Lipoprotein(a) [Lp(a)] is a highly atherogenic low-density lipoprotein-like particle charac

212 rotective high-density lipoproteins (HDL) to atherogenic low-density lipoproteins (LDL).

213 tin plays a role in regulating the uptake of atherogenic low-density lipoproteins in human hepatocyte

214 nol levels in the cecum, as well as elevated atherogenic lysophosphatidylcholine (LPC 18:1) and lysop

215 ders macrophages unable to degrade exogenous atherogenic material and endogenous cargo including dysf

216 ectin provides clues to the inflammatory and atherogenic mechanisms associated with pathological coro

217 We found that atherogenic mice (herein referred to as LDb mice) exhibi

218 Furthermore, when non-atherogenic mice were treated with synthetic LXR agonist

219 ingle miRNA deficiency in diet-induced obese atherogenic mice.

220 ory signaling or by pro-inflammatory and pro-atherogenic microRNAs, miR-155 and miR-33.

221 otentially cardioprotective in patients with atherogenic 'mixed' dyslipidemia.

222 the potential importance of glycation as an atherogenic modification of LDL, factors determining gly

223 F2) is a critical anti-inflammatory and anti-atherogenic molecule in vascular endothelium.

224 DL produced by interaction with CETP had pro-atherogenic or pro-inflammatory properties.

225 nidirectional laminar shear stress (LSS) and atherogenic oscillatory shear stress (OSS).

226 , leading investigators to study the role of atherogenic oxidatively modified lipids (oxylipids).

227 the combination of low shear stress (SS) and atherogenic oxLDL.

228 mice were fed with either a control chow or atherogenic paigen-type diet for 12 weeks.

229 Among women with low total atherogenic particle burden (apolipoprotein B100 level <

230 oprotein cholesterol (LDL-C) levels or total atherogenic particle burden (apolipoprotein B100) is les

231 ures and, for TRL-C, among subjects with low atherogenic particle concentrations (apolipoprotein B <1

232 ts provide evidence of decreased exposure to atherogenic particles in carriers of the minor SORT1 all

233 isk is more closely related to the number of atherogenic particles than to the total mass of choleste

234 in therapy, on-treatment levels of LDL-C and atherogenic particles were associated with residual risk

235 es a measure of cholesterol contained in all atherogenic particles.

236 ant associations for non-HDL cholesterol and atherogenic particles: apolipoprotein B and ion mobility

237 e (GSK) 3alpha/beta in the activation of pro-atherogenic pathways and the accelerated development of

238 -seq approaches identified activation of pro-atherogenic pathways involving a complex interplay of hi

239 ic reticulum stress in the activation of pro-atherogenic pathways.

240 Our results suggest that tolerance to atherogenic peptides increases regulatory T cells which

241 e activation of integrin alpha5beta1 and the atherogenic phenotype of ECs in response to OSS, and pro

242 a powerful therapeutic tool to modulate pro-atherogenic phenotypes and reduce the rate of plaque for

243 We previously showed that macrophages in the atherogenic plaque undergo RIPK3 (receptor-interacting s

244 a bioactive lipid generated by platelets and atherogenic plaques.

245 g values, compared to SS, NASH showed a more atherogenic postprandial lipoprotein profile, an altered

246 with PPAR agonists can reduce the burden of atherogenic postprandial lipoproteins and improve vascul

247 medically important ligands, such as HIV-1, atherogenic postprandial remnant lipoproteins, and molec

248 mellitus (T2DM) impairs hepatic clearance of atherogenic postprandial triglyceride-rich lipoproteins

249 tial inflammatory response that precedes the atherogenic process by targeting different steps of the

250 ndothelium constitutes an early event of the atherogenic process.

251 reas of low ESS, which exacerbates the local atherogenic process.

252 cess during atherosclerosis, thereby linking atherogenic processes and pathological angiogenesis.

253 n genetic factors that facilitate these anti-atherogenic processes remain largely unknown.

254 advances highlight important cell biological atherogenic processes, including mechanotransduction and

255 ment of LDL lipid subfractions toward a less atherogenic profile [decreased small LDL IIIb (-44 +/- 2

256 herogenic towards a pro-inflammatory and pro-atherogenic profile.

257 emonstrated that miR-155 plays a key role in atherogenic programming of macrophages to sustain and en

258 Electronegative L5 LDL exhibits atherogenic properties in vitro and in vivo, and its lev

259 c adipocytes affects the metabolism and anti-atherogenic properties of high-density lipoproteins (HDL

260 We showed that MIF promotes the atherogenic recruitment of monocytes and T cells through

261 receptors for Ccl5 and Ccl2 are important in atherogenic recruitment of neutrophils and monocytes, we

262 Targeting these pro-atherogenic regions is a potential anti-atherogenic ther

263 ) exposed to disturbed flow condition in pro-atherogenic regions.

264 P = 5.5 x 10(-8)), suggesting that targeting atherogenic remnant cholesterol may reduce cardiovascula

265 hrough their metabolic activity decrease pro-atherogenic remnant lipoproteins in hyperlipidemic mice.

266 Atherogenic remodeling often occurs at arterial location

267 rn diet (WD) increase the likelihood for pro-atherogenic remodeling.

268 nknown if old age and/or a WD modify the pro-atherogenic response to disturbed blood flow.

269 will ultimately lead to atheroprotective or atherogenic responses(2).

270 d metalloproteases (ADAMs) and stimulate pro-atherogenic responses, endothelial inflammation and perm

271 EM-1) plays a determinant role in macrophage atherogenic responses.

272 olic alterations, promoting inflammatory and atherogenic responses.

273 f a cohort with detailed characterization of atherogenic risk factors, including surrogate markers of

274 e results suggest that GSK3alpha plays a pro-atherogenic role, possibly by mediating the effects of e

275 cates that T helper 1 (T(H)1) cells have pro-atherogenic roles and regulatory T (T(reg)) cells have a

276 es and regulatory T (T(reg)) cells have anti-atherogenic roles.

277 yancy from less atherogenic lb-LDL to highly atherogenic sd-LDL, restoring the percent distribution o

278 In contrast, serum concentration of atherogenic sdLDL-C >25 mg/dL was predictive of CVD even

279 es during sleep in absence of concurrent pro-atherogenic settings (i.e., genetic propensity or dietar

280 plays a role in the endothelial response to atherogenic shear stress.

281 tly by gender and, in females, a substantial atherogenic shift overlapping the time of menopausal tra

282 n-3 FA inhibit atherogenic signaling pathways and modulate the phenotyp

283 ting uptake of oxidized LDL and inducing pro-atherogenic signaling.

284 Elevated triglycerides are a marker of atherogenic small dense LDL, excess baseline and residua

285 may reflect heightened inflammatory and pro-atherogenic states of the systemic vasculature.

286 ghtens the sensitivity of the vasculature to atherogenic stimuli.

287 xidized low-density lipoprotein (ox-LDL), an atherogenic stimulus, reduced PIAS3 expression, an effec

288 P released from cultured cells in a model of atherogenic stress.

289 of 0.5 ml each for 30 days, in rats, fed an atherogenic suspension.

290 n margarines should be improved by replacing atherogenic TFA and SFA with beneficial ones, in order t

291 Pro-atherogenic TGRL were enriched in eicosapentaenoic acid

292 nd apo A-I and, therefore, appear to be less atherogenic than is a low-fat, high-carbohydrate diet.

293 pro-atherogenic regions is a potential anti-atherogenic therapeutic approach, but it has been extrem

294 acid), less favorable health indices (higher atherogenic, thrombogenic and hypercholesterolemic satur

295 ue secretome from anti-inflammatory and anti-atherogenic towards a pro-inflammatory and pro-atherogen

296 deficiency elevates plasma APOC3 as well as atherogenic triglyceride-rich (TG-rich) lipoproteins (TR

297 (ACS) are treated with statins, which reduce atherogenic triglyceride-rich lipoproteins.

298 originate through the delipidation of larger atherogenic VLDL and large LDL and from direct de novo p

299 uble knockouts (DKOs) and challenged with an atherogenic Western diet.

300 Low-density lipoprotein (LDL) is non-atherogenic, while oxidized LDL (ox-LDL) is critical to